Skip to main content

Update: Reporting Thresholds in USP–NF Monographs

Type of Notice: General Announcement
Posting Date: 23–Jul–2020 

This is an update for the Reporting Threshold in USP–NF Monographs: Proposed Policy Change Compendial Notice, posted on the USP website for public comments from August 13, 2019 to December 31, 2019. In order to facilitate further discussion, USP published comments received from 22 stakeholders who provided permission. 

Based on the comments received, USP determined that removal of reporting thresholds from monographs needed further stakeholder engagement.  Thus, USP intends to host a virtual Roundtable in the Fall of 2020 to continue the discussion on reporting thresholds and other impurities topics. USP looks forward to continued stakeholder engagement including from industry and U.S. Food and Drug Administration (FDA). FDA signaled that they will be providing additional information and context related to reporting thresholds in the near future.  USP intends to incorporate this and all other feedback in the virtual Roundtable session.

In the interim, USP is taking the following actions:

  • USP intends to move previously deferred monographs with reporting thresholds to ballot so that the responsible Expert Committees can approve them for publication, thus ensuring quality updated standards for these substances and drug products. 
  • A new subsection is being proposed for addition to the General Notices and Requirements, 5.60.40. Impurities that are Unusually Toxic and/or Mutagenic. The proposal is presented as a Proposed Interim Revision Announcement in Pharmacopeial Forum (PF) 46(3) [May-Jun 2020], which is open for public comment until July 31, 2020. The new subsection is intended to address potential safety concerns resulting from very toxic impurities not being controlled at appropriate levels in cases where a reporting threshold or disregard limit is included in official USP–NF monographs. 
  • USP intends to move related general chapters <476> Control of Organic Impurities in Drug Substances and Drug Products and <1086> Impurities in Drug Substances and Drug Products to ballot so that the responsible Expert Committee can approve them for publication.

Should you have any questions or comments, please contact Elena Gonikberg, Ph.D., Principal Scientific Liaison, at